Antion Biosciences has developed a proprietary multiplex engineering platform that enables the scalable manufacturing of allogeneic cell and gene therapies with enhanced safety and efficiency. This technology addresses the challenges of hypoimmunogenicity and off-the-shelf availability in CAR T-cell therapies for autoimmune diseases.
Funding
$109.3K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current CAR T-cell therapies face challenges related to safety, specifically the risk of off-target effects and immune rejection, hindering their widespread application, particularly in autoimmune diseases. Manufacturing limitations also restrict the availability of allogeneic, or "off-the-shelf," CAR T-cell therapies, increasing wait times and costs for patients.
Solution
Antion Biosciences has developed a multiplex engineering platform designed to enhance the safety and scalability of allogeneic cell and gene therapies. This platform enables the simultaneous modification of multiple genes within CAR T-cells, reducing the risk of hypoimmunogenicity and enabling the creation of off-the-shelf therapies. By addressing these key limitations, Antion aims to expand the accessibility and effectiveness of CAR T-cell therapies for a broader range of patients, especially those with autoimmune disorders. The technology allows for more precise control over CAR T-cell function, improving safety profiles and therapeutic outcomes.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions involved in the development of cell and gene therapies, particularly those focused on CAR T-cell therapies for autoimmune diseases and oncology.
Features
- Proprietary multiplex engineering platform for simultaneous modification of multiple genes in CAR T-cells.
- Technology designed to reduce hypoimmunogenicity, minimizing the risk of immune rejection in allogeneic therapies.
- Scalable manufacturing process for producing off-the-shelf CAR T-cell therapies.
- Enhanced safety profiles through precise control over CAR T-cell function.